Back Pain Therapy Market: Incur Rapid Extension During 2018 – 2026 By Key Players Celebrex, H.J. Harkins Company, Inc., Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd
According to study published by Centre for Disea0se Control and Prevention (CDC) in 2012, around 20.3% of population was suffering from lower back pain in U.S. Moreover, according to study published by American Chronic Association in 2010, around 80% of population is projected to experience back pain once in a life. Therefore, increasing prevalence of back pain is expected to propel demand for back pain treatment, which in turn is expected to drive growth of global back pain therapy market over the forecast period. Furthermore, increasing ageing population is also expected to drive growth of the market, as chances of back pain increases with the age.
Ask For Highly Informative Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1374
According to study published by National Centre for Biotechnology Information (NCBI) in 2015, around 19.6% of individuals aged between 20 to 60 years were suffering from low back pain worldwide. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, around 547 million people were above 60 years in Asia Pacific region and number is projected to reach around 1.3 billion by 2050. Increasing geriatric population in key regions such as North America, Europe, and Asia Pacific is expected to drive growth of the global back pain therapy market.
Back pain is mainly caused due to muscular strains, strained ligaments, and muscular spasms in any region of the back. Chronic diseases such as herniated discs, arthritis, and osteoporosis can lead to back pain. Depending on the severity of the symptoms, back pain can be categorized- into acute and chronic back pain. Acute pain is most common type of back pain, which can be treated by medication.
Key players operating in back pain therapy market include Celebrex, H.J. Harkins Company, Inc., Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd, Purdue Pharma L.P., Johnson & Johnson, Lupin Ltd., and Teva Pharmaceutical Industries Ltd.
Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1374
North America is expected to hold a dominant position in global back pain therapy market, owing to development of new therapies
In 2017, U.S.-based Pfizer Inc. and Eli Lilly and company received the U.S. Food and Drug Administration (FDA) fast track designation for its drug tanezumab, which is indicated for the treatment of chronic low back pain. Tanezumab is a humanized monoclonal immunoglobulin G2 (IgG2), which could be used as an alternative to opioids. The development of such novel drugs in the U.S. is expected to drive growth of the market in North America. Asia Pacific is expected to be the second largest market for global back pain therapy market due to increasing prevalence of back pain in ageing population.
According to a study published by United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific region constitutes around 60% of the world’s geriatric population. According to study published by World Health Organization (WHO) in 2016, an estimated one out of six people in India are projected to suffer from arthritis once in life.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Back Pain Therapy Market: Incur Rapid Extension During 2018 – 2026 By Key Players Celebrex, H.J. Harkins Company, Inc., Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd here
News-ID: 1720213 • Views: 782
More Releases from Coherent Market Insights - Pharmaceutical Industry
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
More Releases for Asia
RAMPF Korea – Producing in Asia for Asia
Joint Venture for the Asian markets – The international RAMPF Group has realigned the cooperation with its long-standing partner Orient Dosiertechnik from Korea with the founding of RAMPF Korea Co., Ltd. The new company based in Hwaseong City is developing and producing mixing and dispensing systems specifically for the Asian markets. Within the framework of the new joint venture based in Hwaseong City, mixing and dispensing systems are being developed and
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022. 23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property
MES: Expansion in Asia
Berlin, November 24, 2014: Model Engineering Solutions (MES), the Berlin-based specialist for model-based software development, has significantly expanded its business in Asia. In recent years, MES has built up a network of local partners in Japan, Korea, China, and India in order to benefit from the growing market and increasing interest in model-based development and ISO 26262 in Asia. Asia: Driving force in the automotive industry The automotive industry continues
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia Equipping Asia’s navies with the latest diving technology for asymmetric warfare and operations SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting
UDT Asia 2011
Clarion Events hosts the Undersea Defence Technology (UDT) Asia 2011 conference and exhibition to bring senior naval and industry personnel together to cover underwater developments in the region Singapore, May 30 – Clarion Events is hosting UDT Asia on 30 November – 1 December 2011. The event brings together the undersea defence community in Asia, featuring top regional naval speakers, who will be addressing the latest underwater requirements for Asian navies. According
eltherm goes Asia
Finally all preparations are finished and the new subsidiary of eltherm GmbH, eltherm Asia Pacific Pte Ltd has commenced operations in Singapore on 1st April 2010. To celebrate the starting shot, an opening celebration was held in the afternoon of 28th July in the office premises followed by a get together dinner and drinks in the evening at a pub. A total of 62 guests attended the event with the